We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current SUPN market cap is 1.97B. The company's latest EPS is USD 0.0238 and P/E is 1495.80.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 154.34M | 164.52M | 144.74M | 172.68M | 176.71M |
Operating Income | 8.14M | -996k | -3.15M | 22.57M | 40.85M |
Net Income | -15.98M | 1.18M | 124k | 19.92M | 38.5M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 392.76M | 520.4M | 586.31M | 667.75M | 609.04M |
Operating Income | 148.57M | 173.7M | 86.03M | 46.12M | -5.27M |
Net Income | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.29B | 1.28B | 1.3B | 1.32B | 1.34B |
Total Liabilities | 372.97M | 356.16M | 374.92M | 358.38M | 335.55M |
Total Equity | 912.19M | 921.52M | 929.17M | 957.45M | 1.01B |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.16B | 1.5B | 1.69B | 1.7B | 1.28B |
Total Liabilities | 564.85M | 759.24M | 873.3M | 816.3M | 356.16M |
Total Equity | 595.43M | 744.86M | 815.85M | 886.2M | 921.52M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 66.13M | 111.09M | 38.4M | 74.03M | 127.55M |
Investing | 334.71M | 268.73M | -51.62M | -100.22M | -177.23M |
Financing | -398.97M | -397.88M | 1.57M | 3.23M | 6.3M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 143.13M | 138.4M | 127.13M | 116.83M | 111.09M |
Investing | -157.92M | -34.7M | -81.91M | -216.66M | 268.73M |
Financing | 3.93M | 3.56M | -130.42M | -10.48M | -397.88M |
Market Cap | 1.97B |
Price to Earnings Ratio | 1495.80 |
Price to Sales Ratio | 3.23 |
Price to Cash Ratio | 26.19 |
Price to Book Ratio | 2.13 |
Dividend Yield | - |
Shares Outstanding | 55.22M |
Average Volume (1 week) | 422.39k |
Average Volume (1 Month) | 346.24k |
52 Week Change | 21.05% |
52 Week High | 39.37 |
52 Week Low | 25.53 |
Spread (Intraday) | 2.75 (7.39%) |
Company Name | Supernus Pharmaceuticals Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.supernus.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions